Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 08, 2022 16:01 ET
|
Praxis Precision Medicines, Inc.
PRAX-944 Phase 2b Essential1 Study topline results expected in 4Q22; primary endpoint updated to efficacy PRAX-562 Phase 1 study completed, confirming biomarker change and potential for wide...